Edition:
United Kingdom

AcelRx Pharmaceuticals Inc (ACRX.OQ)

ACRX.OQ on NASDAQ Stock Exchange Global Market

4.12USD
4:32pm BST
Change (% chg)

$0.12 (+3.12%)
Prev Close
$4.00
Open
$4.00
Day's High
$4.12
Day's Low
$3.97
Volume
76,419
Avg. Vol
63,321
52-wk High
$5.75
52-wk Low
$1.58

Chart for

About

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product... (more)

Overall

Beta: 3.03
Market Cap(Mil.): $231.44
Shares Outstanding(Mil.): 45.38
Dividend: --
Yield (%): --

Financials

  ACRX.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -1.10 -- --
ROI: -63.23 2.00 14.38
ROE: -- 3.49 16.08

BRIEF-AcelRx Announces FDA Acceptance Of NDA For Dsuvia

* ACELRX PHARMACEUTICALS INC - DSUVIA PDUFA DATE SET FOR NOVEMBER 3, 2018

24 May 2018

BRIEF-Three Arch's Shares Of AcelRx Stock Acquired In Transaction Led By Leerink Revelation Partners And Industry Ventures

* THREE ARCH'S SHARES OF ACELRX COMMON STOCK ACQUIRED IN A PRIVATE TRANSACTION LED BY LEERINK REVELATION PARTNERS AND INDUSTRY VENTURES

23 May 2018

BRIEF-AcelRx Pharmaceuticals Reports Q1 Loss Per Share $0.23

* ACELRX PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

09 May 2018

BRIEF-Acelrx Resubmits New Drug Application For Dsuvia

* ACELRX PHARMACEUTICALS INC - EXPECTS A SIX-MONTH REVIEW BY FDA WITH A PROJECTED PDUFA DATE IN Q4 2018

09 May 2018

BRIEF-AcelRx Receives Positive CHMP Opinion For Dzuveo For Management Of Acute Moderate To Severe Pain In Medically Monitored Settings

* ACELRX RECEIVES POSITIVE CHMP OPINION FOR DZUVEO™ FOR MANAGEMENT OF ACUTE MODERATE TO SEVERE PAIN IN MEDICALLY MONITORED SETTINGS

27 Apr 2018

BRIEF-Acelrx Announces Completion Of The Human Factors Study For Dsuvia And Confirms Plans To Resubmit NDA

* ACELRX ANNOUNCES COMPLETION OF THE HUMAN FACTORS STUDY FOR DSUVIA AND CONFIRMS PLANS TO RESUBMIT NDA IN Q2 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

16 Apr 2018

BRIEF-AcelRx Pharma Q4 Loss Per Share $0.20

* ACELRX PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS

08 Mar 2018

BRIEF-AcelRX Plans To Resubmit The Dsuvia New Drug Application In Q2

* ACELRX ANNOUNCES RECEIPT OF TYPE A FDA MEETING MINUTES AND PLANS TO RESUBMIT THE DSUVIA NEW DRUG APPLICATION IN Q2 2018

08 Mar 2018

Earnings vs. Estimates